Introduction: Infection to Helicobacter pylori has been associated to many gastrointestinal diseases including gastritis, peptic ulcer disease, gastroesophageal reflux disease, atrophic gastritis and gastric cancer. Chronic infections are frequent and severe in patients with diabetes mellitus (DMT2), probably due to the impairment of their immune status. The link between H. pylori infection and diabetes mellitus (DM) remains controversial. This study aimed at detection and comparison of anti H. pylori antibodies (IgG) in serum of diabetes mellitus type 2 (DMT2) and non-diabetic dyspepsia subjects and also to find if there exists any significant correlation between H. pylori infection and DMT2.
Introduction
Infection to spiral rod-shaped gram-negative bacterium, Helicobacter pylori (H. pylori) is associated to many gastrointestinal diseases including gastritis, peptic
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low up at Yaounde Central Hospital, the Cite Verte District Hospital and the Etouge-Ebe Baptist Hospital were included during the three-month period January-April 2017. The control group consisted of 31 healthy students and health personnel with no history of diabetes and hypertension, none of the controls included was on antimicrobial agents, H2 receptor antagonist or proton-pump inhibitor for at least last 4 weeks. Age, sex, height, weight, and body mass index of all the participants were recorded. History of dyspepsia was recorded. The diabetic subjects were also enquired for intake of non-steroidal anti-inflammatory drugs, history of treatment of H. pylori infection, use of proton pump inhibitors, H2 receptor antagonist and antacids. 5 ml of venous blood was aseptically collected in dry tubes, which was kept undisturbed for 1 hour for clot formation. The serum was transferred into sterile cryotubes and stored at -20 °C, for estimation of specific IgG anti H. pylori antibodies and pepsinogen II levels using the HPIgG Elisa and PGII Elisa respectively of the GastroPanel (Biohit plc Finland, www.biohithealthcare.com). All patients with H. pylori IgG ≥ 30 EIU and PGII > 15 μg/l were considered positive for active Helicobacter pylori infection. All the diabetic subjects in study group were observed for various diabetes mellitus related complications like diabetes retinopathy, nephropathy, neuropathy, and diabetic foot. Assay parameters were analysed using a software application GastroSoft (www. GastroPanel.com). Data was interpreted using Epi Info software 7.0. Chi-square test was applied to test the difference between two proportions; student (t) test was applied to test the difference between two means; Fisher (F) test was applied to test the difference of more than two means and P value less than 0.05 was regarded as significant (P < 0.05). Ethical clearance was obtained from the National Ethics committee. All patients signed an informed consent form.
Results
In total, 82 subjects were recruited aged 19-77 yrs, ulcer disease, gastroesophageal reflux disease, atrophic gastritis and gastric cancer [1, 2] . H. pylori infection has been estimated in up to half of the world's population and mainly acquired in childhood by the feco-oral, orooral or gastro-oral routes [3] . H. pylori infection has also been implicated in other non-gastrointestinal diseases like diabetes mellitus, ischemic heart disease, neurological disorder, hypertension, thyroiditis, dermatological, rheumatological and cerebrovascular disease [4] . Diabetes mellitus (DM) is a common, chronic and progressive disease characterized by chronic hyperglycemia with disturbances in carbohydrate, fat and protein metabolism resulting from either absolute or a relative deficiency of insulin and/or action [5] . The chronic hyperglycemia in DM patients is associated with long-term damage, dysfunction, and failure of various organs including the eyes, kidneys, nerves, heart as well as blood vessels. H. pylori has been implicated on cardiovascular conditions, insulin resistance, and metabolic syndrome potentially mediated by elevations in inflammatory markers such as C-reactive protein (CRP) and Interlukin-6 (IL-6) [6] . Several studies all over the world have reported high H. pylori prevalence amongst DM patients although the link between H. pylori infection and diabetes remains controversial. Impairment of cellular and humoral immunity, reduction of gastrointestinal motility and acid secretion, altered glucose metabolism and increased susceptibility of pathogens as they regularly attend hospital settings have been implicated in increased susceptibility to infection in diabetic patient [1] . H. pylori IgG antibodies and pepsinogen II are well known markers for Helicobacter pylori infection and gastric inflammation respectively. Thus, the aim of this study was to evaluate the prevalence of H. pylori infection in DMT2 patients in Yaounde and also to find if there exists any significant correlation between H. pylori infection and DMT2. Significantly raised pepsinogen II levels (PGII > 15 μg/l) were observed in all aged groups of the diabetics (F = 3.1; p = 0.02) than in the non-diabetic group (F = 2.2; p = 0.09). Pepsinogen II levels did not differ statistically between dyspepsia (24.6 ± 16.4 µg/l) and non-dyspepsia subjects (19.9 ± 9.7 µg/l), (t = 1.0; p = 0.31). Raised Pepsinogen II levels were observed in the diabetics presenting with dyspepsia (29.0 ± 17.0 µg/l) than non-diabetics dyspepsia subjects (14.0 ± 8.1 µg/l). No significant difference in the mean Pepsinogen II levels was observed amongst the diabetic complications: Diabetic foot (t = 1.3; p = 0.18); neuropathy (t = 1.43; p = 0.16); nephropathy (t = 1.1; p = 0.27); retinopathy (t = 0.8; p = 0.43). Significantly raised pepsinogen II levels were observed in H. pylori positive (25.2 ± 15.2 μg/l) than negamean 50.0 ± 13.7 yrs. 52 (63.4%) females (aged 19-77, mean 48.7 ± 14.7 yrs) and 30 (36.6%) males aged 29-72, mean 52.3 ± 11.6 yrs. The study included 51 (62.2%) diabetic patients aged 19-72 years (mean age 55.9 ± 9.8 yrs) and 31 (37.2%) healthy controls aged 32-77 years (mean 40.3 ± 13.8 years also reported similar results in a group diabetic patients and healthy controls.
Material and Methods
Significantly raised pepsinogen II levels were observed in H. pylori positive (25.2 ± 15.2 µg/l) t = 2.1; p = 0.03 and a strong positive correlation was obtained between IgG and PGII levels r = 0.98, p = 0.001. Pepsinogen II levels are known to be strongly associated to Helicobacter pylori antibodies [19, 20] (www.biohithealthcare. com). Raised pepsinogen II levels (PGII > 15 μg/l) were observed in all aged groups of the diabetics (F = 3.1; p = 0.02) than in the non-diabetic group (F = 2.2; p = 0.09) and in the diabetics presenting with dyspepsia (29.0 ± 17.0 μg/l) than non-diabetics dyspepsia subjects (14.0 ± 8.1 μg/l). This difference is as a result the increased susceptibility of H. pylori infection in diabetic patients. Pepsinogen II is a known marker of gastric inflammation due to Helicobacter pylori and prolonged use of anti-inflammatory drugs [2, 20] (www.biohithealthcare.com).
Conclusion
The study indicates that diabetics are more prone to H. pylori infection and the growing need for continuous monitoring of H. pylori infection in diabetic patients. However more extensive well-designed cohort studies are needed to definitely conclude the relationship of H. pylori infection with diabetes mellitus and its complications. tive subjects (15.5 ± 17.2 μg/l), t = 2.1; p = 0.03. A strong positive correlation was obtained between IgG and PGII levels r = 0.98, p = 0.001, Figure 1 .
Discussion
In this study, the prevalence of H. pylori seropositivity was 66/82 (80.5%). This prevalence is similar with what had been reported earlier amongst dyspeptic patients in Cameroon by Ebule, et al. [7] (78.7%) and 79.80% respectively in 2017 and 2013 and by Noah, et al.
[8] (81.40%) and in other countries including Benberin, et al. [3] (76.5%). Highest H. pylori antibody seropositivity was observed in subjects above 70 years. There was however no association of H. pylori positivity with age in both the diabetic (p = 0.32) and control group (p = 0.18). Infection to H. pylori has been associated to age [9, 10] . Most of the H. pylori related diseases are associated with male gender [9, 11] . However, we observed an association of H. pylori seropositivity with females 45/52 (86.5%) than males 21/30 (70%), X2 = 3.3; p = 0.04). Similar observations have been reported by Kanbay, et al. [12] and Ali and Sarkis [1] .
Patients with diabetes mellitus are often affected by chronic infections [1] . Many studies have evaluated the prevalence of H. pylori infection in diabetic patients and the possible role of this condition in their metabolic control. The present study found that diabetic patients are more prone to acquire H. pylori infection (88.2%) than the control group (67.7%, p = 0.001) (statistically significant). Jeon, et al. [13] , in a prospective cohort showed that infection of H. pylori leads to an increased incidence of diabetes. Sherwal, et al. [4] and Taher, et al. [14] , also observed higher prevalence of H. pylori in diabetic dyspeptic patients than in non-diabetic. Many other authors across the world including Ali and Sarkis [1] , Kimiaki, et al. [15] , Oldenburg, et al. [9] Quadri, et al. [16] Gulcelik, et al. [17] have also observed statistically significant association of H. pylori with diabetes mellitus. Several reasons have been advanced as to the increased susceptibility to infection in diabetic patients. These include, diabetes-induced impairment of cellular and humeral immunity, diabetes-induced reduction of gastrointestinal motility and acid secretion may promote pathogen colonization and infection rate in the gut, altered glucose metabolism may produce chemical changes in the gastric mucosa that promote H. pylori colonization and frequently exposed to pathogens by diabetics than their healthy counterparts as they regularly attend hospital settings [1, 4] .
The common manifestations and complications observed in H. pylori antibody positive diabetic patients were dyspepsia (86.4%), retinopathy (81.0%), obessity (39.5%), neuropathy (33.3%), hypertension (31.7%), overweight (31.6%), diabetic foot (19.0%), nephropathy (9.5%). These manifestations and complications were also observed among H. pylori seronegative diabetic patients. Gasbarrini, et al. [18] and Sherwal, et al. [4] had
